18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)-Reference-Cited by-同舟云学术

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

Published:2003-09 Issue:14 Volume:39 Page:2012-2020
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Stroobants S.,Goeminne J.,Seegers M.,Dimitrijevic S.,Dupont P.,Nuyts J.,Martens M.,van den Borne B.,Cole P.,Sciot R.,Dumez H.,Silberman S.,Mortelmans L.,van Oosterom A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48,1979

2. New guidelines to evaluate the response to treatment in solid tumors;Therasse;J. Natl. Cancer Inst.,2000

3. The mechanism of accumulation of tumour-localising radiopharmaceuticals;Pauwels;Eur. J. Nucl. Med.,1998

4. Clinical role of positron emission tomography in oncology;Bomanji;Lancet Oncol.,2001

5. Whole-body FDG-PET imaging in the management of patients with cancer;Hustinx;Semin. Nucl. Med.,2002

Cited by 454 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-04-13

2. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review;Frontiers in Pharmacology;2024-02-01

3. Epidemiology, Pathology, Diagnosis, Prevention, and Management of GI Stromal Tumors and Other GI Sarcomas;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

4. A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials;Immunotherapy;2024-01-10

5. Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report;Frontiers in Oncology;2023-12-20